An illustration of osteoporosis. (Science Photo Library/Brand X Pictures/Getty Images) Research points to a key ...

A research team from the Department of Pharmacology and Pharmacy, LKS Faculty of Medicine of the University of Hong Kong ...

Gina Woods, MD, shares three case scenarios of sequential treatment decision-making for long-term therapy and discusses research that can inform clinical decisions.

Efforts to identify older men at risk for osteoporosis and treat those who are eligible received a boost from results reported from a Veterans Affairs (VA) study that showed a significant increase in ...

New study suggests GLP-1 drugs like Ozempic and Wegovy may raise fracture risk by 11% in adults 65 and older with type 2 ...

FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics” or the 'Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and ...

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, ...

The FDA approved Stoboclo and Osenvelt as interchangeable biosimilars for Prolia and XGEVA, enhancing patient access and reducing costs. These biosimilars treat osteoporosis and bone mass loss in ...

Bildyos and Bilprevda are FDA-approved biosimilars to Prolia and Xgeva, expanding access to bone care treatments in the U.S. Bildyos treats osteoporosis and bone loss in cancer therapies, while ...